{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:29:24Z","timestamp":1776882564578,"version":"3.51.2"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences, Iran","doi-asserted-by":"publisher","award":["990240"],"award-info":[{"award-number":["990240"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The Covid-19 virus emerged a few months ago in China and infections rapidly escalated into a pandemic. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To date, there is no selective antiviral agent for the management of pathologies associated with covid-19 and the need for an effective agent against it is essential.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>In this work two home-made databases from synthetic quinolines and coumarins were virtually docked against viral proteases (3CL and PL), human cell surface proteases (TMPRSS2 and furin) and spike proteins (S1 and S2). Chloroquine, a reference drug without a clear mechanism against coronavirus was also docked on mentioned targets and the binding affinities compared with title compounds. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>The best compounds of synthetic coumarins and quinolines for each target were determined. All compounds against all targets showed binding affinity between -5.80 to -8.99 kcal\/mol in comparison with the FDA-approved drug, Chloroquine, with binding affinity of -5.7 to -7.98 kcal\/mol. Two compounds, quinoline-1 and coumarin-24, were found to be effective on three targets \u2013 S2, TMPRSS2 and furin \u2013 simultaneously, with good predicted affinity between -7.54 to -8.85 kcal\/mol. In silico ADME studies also confirmed good oral absorption for them. Furthermore, PASS prediction was calculated and coumarin-24 had higher probable activity (Pa) than probable inactivity (Pi) with acceptable protease inhibitory as well as good antiviral activity against Hepatitis C virus (HCV), Human immunodeficiency virus (HIV) and influenza.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Quinoline-1 and Coumarin-24 have the potential to be used against Covid-19. Hence these agents could be useful in combating covid-19 infection after further in vitro and in vivo studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406417666210208223924","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T06:16:51Z","timestamp":1612937811000},"page":"220-237","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Coumarins and Quinolones as Effective Multiple Targeted Agents Versus\nCovid-19: An In Silico Study"],"prefix":"10.2174","volume":"18","author":[{"given":"Mojgan","family":"Nejabat","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razieh","family":"Ghodsi","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences,\nMashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Hadizadeh","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences,\nMashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/pathogens9050331","volume":"9","author":"Alanagreh L.","year":"2020","unstructured":"Alanagreh L.; Alzoughool F.; Atoum M.; The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens 2020,9(5),331","journal-title":"Pathogens"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/2666796701999200615155630","volume":"1","author":"Miranji K.","year":"2020","unstructured":"Miranji K.; Satish R.; Ramkumar A.; Jagadeeshwara Rao E.; A preliminary review on novel coronavirus disease: COVID-19. Coronaviruses 2020,1(1),90","journal-title":"Coronaviruses"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/1568009620666200414151419","volume":"20","author":"Liu N.N.","year":"2020","unstructured":"Liu N.N.; Tan J.C.; Li J.; Li S.; Cai Y.; Wang H.; COVID-19 pandemic: experiences in china and implications for its prevention and treatment worldwide. Curr Cancer Drug Targets 2020,20(6),410-416","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201021999200820155927","volume":"21","author":"Akilesh S.M.","year":"2020","unstructured":"Akilesh S.M.; Rajesh J.; Palanisamy D.; Wadhwani A.; Repositioning of drugs to counter COVID-19 pandemic - An Insight. Curr Pharm Biotechnol 2020,21,1","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/2666796701999200701131604","volume":"1","author":"Tinsae K.","year":"2020","unstructured":"Tinsae K.; Dharmendra K.; Pramod Kumar S.; Potential drug options for treatment of COVID-19: A review. Coronaviruses 2020,1(1),42","journal-title":"Coronaviruses"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1871530320666200910114259","volume":"20","author":"Thakur P.","year":"2020","unstructured":"Thakur P.; Shrivastava R.; Shrivastava V.K.; Oxytocin as a potential adjuvant against COVID-19 infection. Endocr Metab Immune Disord Drug Targets 2020,20,1","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=7","first-page":"1","volume":"1","author":"Netra P.N.","year":"2020","unstructured":"Netra P.N.; Aman K.D.; Anuj Kumar S.; Amita V.; Off label medication to combat COVID-19: review results to date. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=8","first-page":"8","volume":"5","author":"Narkhede R.R.","year":"2020","unstructured":"Narkhede R.R.; Cheke R.S.; Ambhore J.P.; Shinde S.D.; The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2. Screening 2020,5,8","journal-title":"Screening"},{"key":"ref=9","first-page":"1","volume":"1","author":"Zahid D.","year":"2020","unstructured":"Zahid D.; Lucky C.; Monika C.; Navpreet K.; Tanzeer K.; Neelima D.; An overview of novel coronavirus disease 2019: A global havoc. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bpj.2020.08.022","volume":"120","author":"Peter E.","year":"2021","unstructured":"Peter E.; Schug A.; The inhibitory effect of a Corona virus spike protein fragment with ACE2. Biophys J 2021,120(6),1001-1010","journal-title":"Biophys J"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157016461701190801112325","volume":"17","author":"Ajoy B.","year":"2020","unstructured":"Ajoy B.; Sarmistha B.; Unique Ncov-2019 (Covid-19) spike glycoprotein processing by host protease: analysis and implication on infection. Curr Proteomics 2020,17,1","journal-title":"Curr Proteomics"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/jcm9051473","volume":"9","author":"Kalathiya U.","year":"2020","unstructured":"Kalathiya U.; Padariya M.; Mayordomo M.; Lisowska M.; Nicholson J.; Singh A.; Baginski M.; Fahraeus R.; Carragher N.; Ball K.; Haas J.; Daniels A.; Hupp T.R.; Alfaro J.A.; Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: a novel binding site. J Clin Med 2020,9(5),1473","journal-title":"J Clin Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1386207323999200818162706","volume":"23","author":"Gorla U.S.","year":"2020","unstructured":"Gorla U.S.; Rao G.K.; Kulandaivelu U.S.; Alavala R.R.; Panda S.P.; Lead finding from selected flavonoids with antiviral (SARS-CoV-2) potentials against COVID-19: An in-silico evaluation. Comb Chem High Throughput Screen 2020,23,1","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=14","author":"Sonawane K.","year":"2020","unstructured":"Sonawane K.; Barale S.S.; Dhanavade M.J.; Waghmare S.R.; Nadaf N.H.; Kamble S.A.; Mohammed A.A.; Makandar A.M.; Fandilolu P.M.; Dound A.S.; Homology modeling and docking studies of TMPRSS2 with experimentally known inhibitors Camostat mesylate, nafamostat and bromhexine hydrochloride to control SARS-Coronavirus-2. ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=15","first-page":"1","volume":"1","author":"Suman K.R.","year":"2020","unstructured":"Suman K.R.; Yamini M.; Sukhes M.; Impact and inescapable effects of coronavirus: history to modern pandemic episode. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=16","author":"Ranjan P.","year":"2020","unstructured":"Ranjan P.; Mohapatra B.; Das P.;  A rational drug designing: What\nbioinformatics approach tells about the wisdom of practicing traditional\nmedicines for screening the potential of Ayurvedic and natural\ncompounds for their inhibitory effect against COVID-19 Spike,\nIndian strain Spike, Papain-like protease and Main Protease protein, 2020","journal-title":"A rational drug designing: What\nbioinformatics approach tells about the wisdom of practicing traditional\nmedicines for screening the potential of Ayurvedic and natural\ncompounds for their inhibitory effect against COVID-19 Spike,\nIndian strain Spike, Papain-like protease and Main Protease protein,"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157340641601191209150546","volume":"16","author":"Kiran C.","year":"2020","unstructured":"Kiran C.; Runali S.; Farmiza B.; Nalini S.; Nitesh K.; Anoop K.; Rekha R.S.; Rao C.M.; Kavitha S.; In silico study to evaluate the antiviral activity of novel structures against 3C-like protease of novel coronavirus (COVID-19) and SARSCoV. Med Chem 2020,16,1","journal-title":"Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.2174\/1568026620666200704135327","volume":"20","author":"Nayarisseri A.","year":"2020","unstructured":"Nayarisseri A.; Khandelwal R.; Madhavi M.; Selvaraj C.; Panwar U.; Sharma K.; Hussain T.; Singh S.K.; Shape-based machine learning models for the potential novel COVID-19 protease inhibitors assisted by molecular dynamics simulation. Curr Top Med Chem 2020,20(24),2146-2167","journal-title":"Curr Top Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/2666796701999200701122817","volume":"1","author":"Sivaraman D.","year":"2020","unstructured":"Sivaraman D.; Pradeep P.S.; Manoharan S.S.; Bhat C.R.; Leela K.V.; Venugopal V.; Revealing potential binding affinity of FDA approved therapeutics targeting main protease (3CLpro) in Impairing novel coronavirus (SARSCoV- 2) replication that causes COVID-19. Coronaviruses 2020,1(1),98","journal-title":"Coronaviruses"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1016\/j.bmc.2016.05.013","volume":"24","author":"Kumar V.","year":"2016","unstructured":"Kumar V.; Tan K-P.; Wang Y-M.; Lin S-W.; Liang P-H.; Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem 2016,24(13),3035-3042","journal-title":"Bioorg Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"Pillaiyar T.","year":"2016","unstructured":"Pillaiyar T.; Manickam M.; Namasivayam V.; Hayashi Y.; Jung S-H.; An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 2016,59(14),6595-6628","journal-title":"J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.2174\/1568026620666200710105507","volume":"20","author":"Shanmugam A.","year":"2020","unstructured":"Shanmugam A.; Muralidharan N.; Velmurugan D.; Gromiha M.M.; Therapeutic targets and computational approaches on drug development for COVID-19. Curr Top Med Chem 2020,20(24),2210-2220","journal-title":"Curr Top Med Chem"},{"key":"ref=23","first-page":"1","volume":"1","author":"Ahmed Adebayo I.","year":"2020","unstructured":"Ahmed Adebayo I.; Nnaemeka Tobechukwu A.; Homology modeling of coronavirus structural proteins and molecular docking of potential drug candidates for the treatment of COVID-19. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=24","author":"Arya R.","year":"2020","unstructured":"Arya R.; Das A.; Prashar V.; Kumar M.; Potential inhibitors against papain-like protease of novel coronavirus (COVID-19) from FDA approved drugs. ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"Gordon C.J.","year":"2020","unstructured":"Gordon C.J.; Tchesnokov E.P.; Woolner E.; Perry J.K.; Feng J.Y.; Porter D.P.; G&#xF6;tte M.; Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020,295(20),6785-6797","journal-title":"J Biol Chem"},{"key":"ref=26","first-page":"1","volume":"1","author":"Chandra M.","year":"2020","unstructured":"Chandra M.; Vinod K.; COVID-19: A comparative study of SARS, MERS and COVID-19. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488551501200114144207","volume":"15","author":"Harshal Ashok P.","year":"2020","unstructured":"Harshal Ashok P.; Anjali Harshal P.; Sandip Ashok P.; Prashant Ashok P.; CORONAVIRUS and COVID-19: A systematic review and perspective. Curr Drug Ther 2020,15,1","journal-title":"Curr Drug Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.3390\/molecules25102271","volume":"25","author":"Rahman N.","year":"2020","unstructured":"Rahman N.; Basharat Z.; Yousuf M.; Castaldo G.; Rastrelli L.; Khan H.; Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules 2020,25(10),2271","journal-title":"Molecules"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2174\/1389200221666200711160440","volume":"21","author":"Yao X.","year":"2020","unstructured":"Yao X.; Hou Z.; Cui C.; Zhang M.; Tu S.; Li H.; Liu D.; Updates on the pharmacology of chloroquine against coronavirus disease 2019 (COVID-19): A perspective on its use in the general and geriatric population. Curr Drug Metab 2020,21(7),534-540","journal-title":"Curr Drug Metab"},{"key":"ref=30","first-page":"1","volume":"21","author":"Abdul Alim Md.","year":"2020","unstructured":"Abdul Alim Md.; A.-B., Facts and myths: efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19. Curr Drug Targets 2020,21,1","journal-title":"Curr Drug Targets"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1871526520666200726224802","volume":"20","author":"Abd-Elsalam S.","year":"2020","unstructured":"Abd-Elsalam S.; Elkadeem M.; Glal K.A.; Chloroquine as chemoprophylaxis for COVID-19: Will this work? Infect Disord Drug Targets 2020,20,1","journal-title":"Infect Disord Drug Targets"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106012","volume":"56","author":"Yu R.","year":"2020","unstructured":"Yu R.; Chen L.; Lan R.; Shen R.; Li P.; Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents 2020,56(2)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138161282601200225102049","volume":"26","author":"Evellyn Claudia Wietzikoski L.","year":"2020","unstructured":"Evellyn Claudia Wietzikoski L.; Lorena Neris B.; Samantha W.; Repurposing drugs for the management of patients with confirmed coronavirus disease 2019 (COVID-19). Curr Pharm Des 2020,26,1","journal-title":"Curr Pharm Des"},{"key":"ref=34","first-page":"1","volume":"17","author":"Kaushik S.","year":"2020","unstructured":"Kaushik S.; Rajesh Kumar D.; Preliminary identification of hamamelitannin and rosmarinic acid as COVID-19 inhibitors based on molecular docking. Lett Drug Des Discov 2020,17,1","journal-title":"Lett Drug Des Discov"},{"key":"ref=35","first-page":"1","volume":"1","author":"Viney C.","year":"2020","unstructured":"Viney C.; Pooja A.C.; COVID-19: The unprecedented malady- a holistic review. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=36","first-page":"1","volume":"1","author":"Rohini S.K.","year":"2020","unstructured":"Rohini S.K.; Sachin M.M.; Coordinated roadmap to grip pandemic COVID-19. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=37","first-page":"1","volume":"\u2022","author":"Cel\u0131\u0307k I.","year":"2020","unstructured":"Cel\u0131\u0307k I.; Onay-Bes\u0131\u0307kc\u0131\u0307 A.; Ayhan-Kilcig\u0131\u0307l G.J.J.B.S.; Dynamics, Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. J Biomol Struct Dyn 2020,\u2022,1","journal-title":"J Biomol Struct Dyn"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejmech.2016.07.056","volume":"123","author":"Hassan M.Z.","year":"2016","unstructured":"Hassan M.Z.; Osman H.; Ali M.A.; Ahsan M.J.; Therapeutic potential of coumarins as antiviral agents. Eur J Med Chem 2016,123,236-255","journal-title":"Eur J Med Chem"},{"key":"ref=39","author":"Breidenbach J.","unstructured":"Breidenbach J.; Bartz U.; G&#xFC;tschow M.;  Coumarin as a structural component of substrates and probes for serine and cysteine proteasesBiochimica et Biophysica Acta (BBA)-Proteins and Proteomics,\t2020, 140445","journal-title":"Coumarin as a structural component of substrates and probes for serine and cysteine proteasesBiochimica et Biophysica Acta (BBA)-Proteins and Proteomics,\t2020, 140445"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1386207323666200814132149","volume":"23","author":"Talluri S.","year":"2020","unstructured":"Talluri S.; Molecular docking and virtual screening based prediction of drugs for COVID-19. Comb Chem High Throughput Screen 2020,23,1","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/1573403X16666200621154842","volume":"16","author":"Kulkarni P.","year":"2020","unstructured":"Kulkarni P.; Mahadevappa M.; Alluri S.; COVID-19 pandemic and the impact on the cardiovascular disease patient care. Curr Cardiol Rev 2020,16(3),173-177","journal-title":"Curr Cardiol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/2666796701999200621203144","volume":"1","author":"Yadollah Abolfathi M.","year":"2020","unstructured":"Yadollah Abolfathi M.; The COVID-19 and Ageism in Social Media. Coronaviruses 2020,1(1),7","journal-title":"Coronaviruses"},{"key":"ref=43","first-page":"1","volume":"18","author":"Muhammad Imran D.","year":"2020","unstructured":"Muhammad Imran D.; Jawayria N.; Maryam Zaheer K.; Rida K.; Coronavirus disease-19 (COVID-19): systematic analysis of situation in Pakistan-responses and potential advancements. Antiinfect Agents 2020,18,1","journal-title":"Antiinfect Agents"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0929867327666200702151018","volume":"27","author":"Kumar R.","year":"2020","unstructured":"Kumar R.; Harilal S.; Al-Sehemi A.G.; Mathew G.E.; Carradori S.; Mathew B.; The Chronicle of COVID-19 and possible strategies to curb the pandemic. Curr Med Chem 2020,27,1","journal-title":"Curr Med Chem"},{"key":"ref=45","year":"2020","unstructured":"S., CS.; Madathilkovilakathu, H. Drug repurposing for COVID-19 from FDA approved and experiment stage drugs by in silico methods with SARS CoV-2 spike protein. ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=46","author":"Barik A.","year":"2020","unstructured":"Barik A.; Rai G.; Modi G.;  Molecular docking and binding mode\nanalysis of selected FDA approved drugs against COVID-19 selected\nkey protein targets: An effort towards drug repurposing to\nidentify the combination therapy to combat COVID-19 arXiv preprint, 2020","journal-title":"Molecular docking and binding mode\nanalysis of selected FDA approved drugs against COVID-19 selected\nkey protein targets: An effort towards drug repurposing to\nidentify the combination therapy to combat COVID-19 arXiv preprint,"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389557520999200824103803","volume":"20","author":"Sanghai N.","year":"2020","unstructured":"Sanghai N.; Shafiq K.; Tranmer G.K.; Drug discovery by drug repurposing: combating COVID-19 in the 21st century. Mini Rev Med Chem 2020,20,1","journal-title":"Mini Rev Med Chem"},{"key":"ref=48","first-page":"1","volume":"1","author":"Silvana Mirella A.","year":"2020","unstructured":"Silvana Mirella A.; Francesco De C.; Giovanni B.; Rosario C.; Mario C.; Dealing with COVID-19: lessons learned from the Italian experience. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1573398X1601200730113714","volume":"16","author":"Farzaneh S.","year":"2020","unstructured":"Farzaneh S.; COVID 19, All a Radiologist Needs to Know: A Narrative Review. Curr Respir Med Rev 2020,16,1","journal-title":"Curr Respir Med Rev"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488551501200114144207","volume":"15","author":"Smriti O.","year":"2020","unstructured":"Smriti O.; Hina C.; Seema M.; COVID-19: pathogenesis and pharmacological basis for use of passive antibody therapy. Curr Drug Ther 2020,15,1","journal-title":"Curr Drug Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1386207323999200820162551","volume":"23","author":"Dubey R.","year":"2020","unstructured":"Dubey R.; Dubey K.; Molecular docking studies of bioactive nicotiflorin against 6W63 novel coronavirus 2019 (COVID-19). Comb Chem High Throughput Screen 2020,23,1","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1386207323999200824115536","volume":"23","author":"Nandi S.","year":"2020","unstructured":"Nandi S.; Kumar M.; Saxena M.; Saxena A.K.; The antiviral and antimalarial drug repurposing in quest of chemotherapeutics to combat COVID-19 utilizing structure-based molecular docking. Comb Chem High Throughput Screen 2020,23,1","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/14756366.2014.1003215","volume":"31","author":"Park J-Y.","year":"2016","unstructured":"Park J-Y.; Ko J-A.; Kim D.W.; Kim Y.M.; Kwon H-J.; Jeong H.J.; Kim C.Y.; Park K.H.; Lee W.S.; Ryu Y.B.J.J.i.; Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem 2016,31(1),23-30","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejmech.2017.03.024","volume":"132","author":"Abdizadeh T.","year":"2017","unstructured":"Abdizadeh T.; Kalani M.R.; Abnous K.; Tayarani-Najaran Z.; Khashyarmanesh B.Z.; Abdizadeh R.; Ghodsi R.; Hadizadeh F.; Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents. Eur J Med Chem 2017,132,42-62","journal-title":"Eur J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103711","volume":"98","author":"Mirzaei S.","year":"2020","unstructured":"Mirzaei S.; Eisvand F.; Hadizadeh F.; Mosaffa F.; Ghasemi A.; Ghodsi R.; Design, synthesis and biological evaluation of novel 5,6,7-trimethoxy-N-aryl-2-styrylquinolin-4-amines as potential anticancer agents and tubulin polymerization inhibitors. Bioorg Chem 2020,98","journal-title":"Bioorg Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3184\/174751917X14859570937677","volume":"41","author":"Ghanei-Nasab S.","year":"2017","unstructured":"Ghanei-Nasab S.; Nadri H.; Moradi A.; Marjani A.; Shabani S.; Firoozpour L.; Moghimi S.; Khoobi M.; Hadizadeh F.; Foroumadi A.; Synthesis and anti-acetylcholinesterase activity of N-[(indolyl) ethyl)-coumarin-yloxy)] alkanamides. J Chem Res 2017,41(2),120","journal-title":"J Chem Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s13738-012-0093-4","volume":"9","author":"Zarchi M.A.K.","year":"2012","unstructured":"Zarchi M.A.K.; Nejabat M.; Convenient synthesis of alkyl thioacetate from alkyl halide using a polymer-supported sodium thioacetate. J Iran Chem Soc 2012,9(5),767","journal-title":"J Iran Chem Soc"},{"key":"ref=58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1501240","volume":"2","author":"Chen D.","year":"2016","unstructured":"Chen D.; Oezguen N.; Urvil P.; Ferguson C.; Dann S.M.; Savidge T.C.; Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci Adv 2016,2(3)","journal-title":"Sci Adv"},{"key":"ref=59","first-page":"1","volume":"2","author":"Bittmann S.","year":"2020","unstructured":"Bittmann S.; Luchter E.; Weissenstein A.; Villalon G.; Moschuring-Alieva E.; TMPRSS2-inhibitors play a role in cell entry mechanism of COVID-19: an insight into camostat and nefamostat. J Regen Biol Med 2020,2(2),1","journal-title":"J Regen Biol Med"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.022","author":"Mousavizadeh L.","year":"2020","unstructured":"Mousavizadeh L.; Ghasemi S.; Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2020","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46570\/utjms.vol7-2020-361","volume":"7","author":"Jankun J.","year":"2020","unstructured":"Jankun J.; COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs. Translation. The University of Toledo Journal of Medical Sciences 2020,7,1","journal-title":"The University of Toledo Journal of Medical Sciences"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Schroeder S.; Kleine-Weber H.; M&#xFC;ller M.A.; Drosten C.; P&#xF6;hlmann S.; Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrob Agents Chemother 2020,64(6),e00754-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0250688201901010001","volume":"1","author":"Aaron H.","year":"2020","unstructured":"Aaron H.; Janet H.; Flu Viral Multiplex Testing and its Implication for COVID-19 Testing. New Emirates Medical Journal 2020,1,1","journal-title":"New Emirates Medical Journal"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570159X18666200507085335","volume":"18","author":"Li J.","year":"2020","unstructured":"Li J.; Long X.; Zhang Q.; Fang X.; Fang F.; Lv X.; Zhang D.; Sun Y.; Li N.; Hu S.; Lin Z.; Xiong N.; Emerging evidence for neuropsycho-consequences of COVID-19. Curr Neuropharmacol 2020,18,1","journal-title":"Curr Neuropharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/2666796701999200617161348","volume":"1","author":"Tansukh B.","year":"2020","unstructured":"Tansukh B.; Praveen Kumar T.; Mukesh M.; COVID-19: morphology, characteristics, symptoms, prevention, clinical diagnosis and current scenario. Coronaviruses 2020,1(1),82","journal-title":"Coronaviruses"},{"key":"ref=66","first-page":"1","volume":"1","author":"Yadollah Abolfathi M.","year":"2020","unstructured":"Yadollah Abolfathi M.; The COVID-19 and Munchausen Syndrome. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"Hirano T.","year":"2020","unstructured":"Hirano T.; Murakami M.; COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020,52(5),731-733","journal-title":"Immunity"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1386207323666200806164635","volume":"23","author":"Wang M.","year":"2020","unstructured":"Wang M.; Fu D.; Yao L.; Li J.; Theoretical study of the molecular mechanism of maxingyigan decoction against COVID-19: network pharmacology-based strategy. Comb Chem High Throughput Screen 2020,23,1","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0929867327666200903115138","volume":"27","author":"Anwar F.","year":"2020","unstructured":"Anwar F.; Naqvi S.; Al-Abbasi F.A.; Neelofar N.; Kumar V.; Sahoo A.; Kamal M.A.; Targeting COVID-19 in Parkinson\u2019s patients: Drugs repurposed. Curr Med Chem 2020,27,1","journal-title":"Curr Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2174\/1568026620999200517043137","volume":"20","author":"Sternberg A.","year":"2020","unstructured":"Sternberg A.; McKee D.L.; Naujokat C.; Novel drugs targeting the SARS-CoV-2\/COVID-19 machinery. Curr Top Med Chem 2020,20(16),1423-1433","journal-title":"Curr Top Med Chem"},{"key":"ref=71","first-page":"1","volume":"1","author":"Victor F.","year":"2020","unstructured":"Victor F.; Favipiravir in the spotlight: In search of treatment against COVID-19. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cmdc.201800807","volume":"14","year":"2019","unstructured":"ChemMedChem Van Lam van, T.; Ivanova, T.; Hardes, K.; Heindl, M.R.; Morty, R.E.; B&#xF6;ttcher-Friebertsh&#xE4;user, E.; Lindberg, I.; Than, M.E.; Dahms, S.O.; Steinmetzer, T. Design, synthesis, and characterization of macrocyclic inhibitors of the proprotein convertase furin.2019,14(6),673-685","journal-title":"ChemMedChem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1779129","author":"Prasanth D.S.N.B.K.","year":"2020","unstructured":"Prasanth D.S.N.B.K.; Murahari M.; Chandramohan V.; Panda S.P.; Atmakuri L.R.; Guntupalli C.; In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2. J Biomol Struct Dyn 2020,1-15","journal-title":"J Biomol Struct Dyn"},{"key":"ref=74","first-page":"1","volume":"1","author":"Alice Barros C.","year":"2020","unstructured":"Alice Barros C.; Igor Augusto B.; Study of the relationships between COVID-19, associated diseases, and vitamins. Coronaviruses 2020,1,1","journal-title":"Coronaviruses"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1871526520666200905123941","volume":"20","author":"Jadhav N.V.","year":"2020","unstructured":"Jadhav N.V.; Singh N.; Targhotra M.; Chauhan M.K.; Impact of COVID-19 on indian pharmaceutical industry and wayforward. Infect Disord Drug Targets 2020,20,1","journal-title":"Infect Disord Drug Targets"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210208223924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/191241\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210208223924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:07:00Z","timestamp":1652184420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/191241\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406417666210208223924","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}